Today: 29 June 2026
Browse Category

NASDAQ:BDRX 10 December 2025

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2 This article looks at where BDRX stock stands on December 10, 2025, the latest clinical and regulatory news from Biodexa, the company’s increasingly complex capital structure, and how third‑party models and analysts are framing the risk–reward profile into 2026.
10 December 2025
··
Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

U.S. stock futures are edging higher early Wednesday as traders brace for the Federal Reserve’s final policy decision of 2025, with markets pricing in a high probability of another 25‑basis‑point rate cut. Futures on the Nasdaq 100, S&P 500 and Dow are modestly green, while the 10‑year U.S. Treasury yield hovers near 4.18% and commodities like silver trade at record highs above $61 an ounce. TipRanks+1 Beneath the calm surface of the indexes, however, the real fireworks are in pre‑market trading. A handful of thinly traded SPACs and micro‑cap biotechs are posting triple‑digit gains, joined by a distressed hotel REIT and a Hong Kong security‑services operator.
10 December 2025
··········

Stock Market Today

  • Ross Stores (NASDAQ:ROST) tops Q1 estimates, outpaces discount peers on revenue
    June 29, 2026, 3:43 PM EDT. Ross Stores (NASDAQ:ROST) pulled in $6.01 billion in revenue for Q1, up 20.6% from a year ago and 6.6% over forecasts, leading discount retail. The off-price chain kept customer traffic strong with sales of excess inventory at deep discounts. CEO Jim Conroy pointed to good execution, marketing, and a boost from tax refund spending. Still, shares of discount retailers dropped about 4.5% after earnings, as investors weighed worries around e-commerce and lower mall traffic. Ross stays focused on its value model as retail faces mixed signals.
Go toTop